Search results for "slip"

showing 10 items of 471 documents

Lipoprotein abnormalities in chronic kidney disease and renal transplantation

2021

Chronic kidney disease (CKD) is one of the most important risk factors for cardiovascular disease (CVD). Despite the kidney having no direct implications for lipoproteins metabolism, advanced CKD dyslipidemia is usually present in patients with CKD, and the frequent lipid and lipoprotein alterations occurring in these patients play a role of primary importance in the development of CVD. Although hypertriglyceridemia is the main disorder, a number of lipoprotein abnormalities occur in these patients. Different enzymes pathways and proteins involved in lipoprotein metabolism are impaired in CKD. In addition, treatment of uremia may modify the expression of lipoprotein pattern as well as deter…

medicine.medical_specialtyLipoproteins030232 urology & nephrologyDiseaseReview030204 cardiovascular system & hematologyurologic and male genital diseasesGastroenterologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineChronic kidney diseasemedicinelcsh:ScienceEcology Evolution Behavior and SystematicsKidneybusiness.industryHypertriglyceridemiaPaleontologymedicine.diseaseCardiovascular diseaseLipidsUremiafemale genital diseases and pregnancy complicationsTransplantationmedicine.anatomical_structureSpace and Planetary Sciencelipids (amino acids peptides and proteins)lcsh:QbusinessDyslipidemiaKidney diseaseLipoprotein
researchProduct

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.

2004

Type 2 diabetes is an important cardiovascular risk factor. A significant component of the risk associated with type 2 diabetes is thought to be because of its characteristic lipid "triad" profile of raised small dense low-density lipoprotein levels, lowered high-density lipoprotein, and elevated triglycerides (TGs). Trials of statins and fibrates have included substantial numbers of patients with diabetes and indicate that lipid lowering reduces cardiovascular event rates in these patients. However, statins alone do not always address all the lipid abnormalities of diabetes. Fibrates, which have low affinity for peroxisome proliferator-activated receptor alpha (PPARalpha), improve most asp…

medicine.medical_specialtyLipoproteinsPeroxisome proliferator-activated receptorType 2 diabetesInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineLipolysisHumansPPAR alphaDyslipidemiaschemistry.chemical_classificationbusiness.industrynutritional and metabolic diseasesLipid metabolismmedicine.diseaseLipid MetabolismEndocrinologychemistryDiabetes Mellitus Type 2Cardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaLipoproteinAmerican heart journal
researchProduct

El papel de la dislipemia aterogénica en las guías de práctica clínica.

2016

Background and objective Atherogenic dyslipidaemia is underdiagnosed, undertreated, and under-controlled. The aim of the present study was to assess the positioning of clinical guidelines as regards atherogenic dyslipidaemia. Material and method The major clinical guidelines of scientific societies or official agencies issued between January 1, 2012 and March 31, 2015 were collected from the MEDLINE database. High-density lipoprotein (HDL) cholesterol, triglycerides, atherogenic dyslipidaemia, non-HDL cholesterol, and apolipoprotein (apo) B were gathered from the 10 selected guidelines, and it was assessed whether these parameters were considered a cardiovascular risk factor, a therapeutic …

medicine.medical_specialtyLow HDL-cholesterolendocrine system diseasesApolipoprotein BNice030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCardiovascular preventionInternal medicinemental disordersmedicinePharmacology (medical)cardiovascular diseases030212 general & internal medicineRisk factorcomputer.programming_languagebiologybusiness.industryCholesterolnutritional and metabolic diseasesClinical Practicechemistrybiology.proteinlipids (amino acids peptides and proteins)Atherogenic dyslipidaemia Cardiovascular prevention Cholesterol Colesterol Dislipemia aterogénica Guías de práctica clínica Lipids Lípidos Practice guidelines Prevención cardiovascular Triglicéridos TriglyceridesCardiology and Cardiovascular MedicinebusinesscomputerLipoprotein
researchProduct

2014

Objectives While a bidirectional relationship between diabetes and depression has been established, there is little knowledge if the associations are due to somatic-affective or cognitive-affective dimensions of depression.

medicine.medical_specialtyMultidisciplinarybusiness.industryDiabetes mellitusMedicineAnxietymedicine.symptombusinessmedicine.diseasePsychiatryObesityDepression (differential diagnoses)DyslipidemiaPLOS ONE
researchProduct

Tannerella forsythia is associated with increased levels of atherogenic low density lipoprotein and total cholesterol in chronic periodontitis

2015

Background: Accumulating evidence suggests that acute and chronic infections with periodontopathogens are associated with an increased risk of cardiovascular disease. The objective of this study was to assess whether Tannerella forsythia and Porphyromonas gingivalis are associated with increased levels of atherogenic low-density lipoprotein (LDL), high-density lipoprotein, total cholesterol (TC), triglycerides and body mass index (BMI) in chronic periodontitis patients. Material and Methods: Medical history and clinical and radiographic examination were conducted in 80 chronic periodontitis patients and 28 healthy individuals. Fasting blood samples were drawn for the measurement of the para…

medicine.medical_specialtyOdontologíaGastroenterologychemistry.chemical_compoundForsythiaInternal medicinemedicineTannerella forsythiaPeriodontologyGeneral DentistryPeriodontitisbiologybusiness.industryResearchmedicine.diseasebiology.organism_classification:CIENCIAS MÉDICAS [UNESCO]Chronic periodontitisCiencias de la saludstomatognathic diseaseschemistryLow-density lipoproteinUNESCO::CIENCIAS MÉDICASImmunologybusinessBody mass indexDyslipidemiaLipoprotein
researchProduct

Cardiovascular risk and events in polycystic ovary syndrome

2009

Young women with polycystic ovary syndrome (PCOS) present a high risk for cardiovascular disease because of the presence of abdominal obesity, insulin resistance and androgen excess. In addition, they present with endothelial dysfunction and early signs of atherosclerosis (increased carotid intima-media thickness and increased coronary calcium). However, the evidence of increased cardiovascular events during the postmenopausal age is relatively small, although some recent studies have indicated a slight increase in the severity of cardiovascular disease in women who had PCOS during their fertile age. The discrepancy between cardiovascular risk in young age and postmenopausal cardiovascular …

medicine.medical_specialtyPCOS Cardiovascular risk myocardial infarction stroke atherosclerosisSettore MED/09 - Medicina InternaDiseaseAndrogen ExcessSeverity of Illness IndexSettore MED/13 - EndocrinologiaInsulin resistanceRisk FactorsInternal medicinePrevalencemedicineHumansEndothelial dysfunctionAbdominal obesityEvidence-Based Medicinebusiness.industryHyperandrogenismObstetrics and GynecologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryPostmenopauseEndocrinologyPremenopauseCardiovascular DiseasesFemalemedicine.symptombusinessDyslipidemiaPolycystic Ovary SyndromeClimacteric
researchProduct

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

2020

Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of qua…

medicine.medical_specialtyRare dyslipidaemiaConsensusSettore MED/09 - Medicina InternaGenotypediagnosisEndocrinology Diabetes and MetabolismMEDLINE030209 endocrinology & metabolism610 Medicine & health03 medical and health sciences0302 clinical medicineEndocrinologyRare DiseasesGenotype540 ChemistryInternal Medicinemedicinegeneome sequencingHumansgeneticsGenetic Predisposition to DiseaseRare dyslipidemias; genetics; diagnosis; treatment030212 general & internal medicineDisease management (health)Intensive care medicineHealth policyDyslipidemias10038 Institute of Clinical Chemistrytreatmentbusiness.industryTask forcegene therapiesDisease ManagementAtherosclerosisPhenotype1310 EndocrinologyEurope2712 Endocrinology Diabetes and MetabolismPhenotype2724 Internal MedicinePractice Guidelines as TopicRare dyslipidemiasEuropean atherosclerosis societylipids (amino acids peptides and proteins)businessQuality information
researchProduct

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study

2021

Abstract Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis…

medicine.medical_specialtyRegistryStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyGuidelinesSecondary care03 medical and health sciences0302 clinical medicineEzetimibeRisk FactorsInternal medicinemedicineHumans030212 general & internal medicinePCSK9 InhibitorsDyslipidemiasSecondary preventionPrimary Health Carebusiness.industryAnticholesteremic AgentsStatinsCholesterol LDLGuidelineLipidsConfidence intervalCross-Sectional StudiesTreatment OutcomeCholesterolCardiovascular DiseasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugDA VINCI study
researchProduct

Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Network

2020

ABSTRACTBackgroundSpain has been one of the countries most affected by the COVID-19 pandemic.ObjectiveTo create a registry of patients with COVID-19 hospitalized in Spain in order to improve our knowledge of the clinical, diagnostic, therapeutic, and prognostic aspects of this disease.MethodsA multicentre retrospective cohort study, including consecutive patients hospitalized with confirmed COVID-19 throughout Spain. Epidemiological and clinical data, additional tests at admission and at seven days, treatments administered, and progress at 30 days of hospitalization were collected from electronic medical records.ResultsUp to April 30th 2020, 6,424 patients from 109 hospitals were included. …

medicine.medical_specialtyRespiratory distressbusiness.industryMortality rateMedical recordHydroxychloroquineRetrospective cohort studyLopinavirmedicine.diseaseInternal medicineEpidemiologymedicinebusinessDyslipidemiamedicine.drug
researchProduct

Fructose and cardiometabolic disorders: the controversy will, and must, continue

2010

The present review updates the current knowledge on the question of whether high fructose consumption is harmful or not and details new findings which further pushes this old debate. Due to large differences in its metabolic handling when compared to glucose, fructose was indeed suggested to be beneficial for the diet of diabetic patients. However its growing industrial use as a sweetener, especially in soft drinks, has focused attention on its potential harmfulness, possibly leading to dyslipidemia, obesity, insulin resistance/metabolic syndrome and even diabetes. Many new data have been generated over the last years, confirming the lipogenic effect of fructose as well as risks of vascular…

medicine.medical_specialtyReviewFructoseBiologyBioinformaticschemistry.chemical_compoundInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineHumansVascular DiseasesTriglyceridesHypertriglyceridemialcsh:R5-920HypertriglyceridemiaFructoseGeneral Medicinemedicine.diseaseObesityMetabolic syndromeDietEndocrinologychemistryLiverSweetening AgentsHypertensionUric acidMetabolic syndromelcsh:Medicine (General)Uric acidDyslipidemiaClinics
researchProduct